Inhibrx Biosciences, Inc. INBX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on assets | -61%— | —— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 6.5×+2.5× | 3.9×-0.6× | 4.5×-0.5× | 5×-0.1× | 5.1×— | |
| Quick ratio | 6.5×+2.5× | 3.9×-0.6× | 4.5×-0.5× | 5×-0.1× | 5.1×— | |
| Cash ratio | 6.1×+2.4× | 3.7×-0.6× | 4.3×-0.5× | 4.8×-0.2× | 5×— | |
| Leverage | ||||||
| Debt-to-assets | 1×+0.3× | 0.7×+0.1× | 0.6×+0.1× | 0.5×+0.1× | 0.4×— | |
| Interest coverage | -9.5×+1.6× | -11.1×+6.0× | -17.1×+11.6× | -28.6×+8.7× | -37.3×-12.8× | |
| Per Share | ||||||
| Book value per share | -$1.35-362% | $0.52-78.3% | $2.38-46.3% | $4.43-27.4% | $6.11-31.5% | |
| Valuation | ||||||
| Market capitalization | $1.4B+547% | $1.15B+136% | $487.87M+128% | $213.66M+5.5% | $202.52M-9.2% | |
| Enterprise value | $1.42B+1,236% | $1.13B+156% | $441.69M+230% | $133.89M+44.7% | $92.53M— | |
| Free cash flow yield | -9.4%+68.6pp | -11.3%+18.1pp | -29.4%+36.2pp | -65.6%+17.7pp | -83.3%— | |
| Earnings yield | -9.3%-829pp | -12.2%+9.8pp | -22%+32.2pp | -54.2%-929pp | 874.4%+95.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Inhibrx Biosciences, Inc.'s ratios come from?
- Every ratio is computed from Inhibrx Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
